Medical AI
Quality Guardrails to Build Before Scaling Medical AI
Medical AI should not be treated as a simple tool rollout. Based on WHO guidance and FDA documents, this article explains how companies can set up governance, monitoring, and change control before quality breaks down.
Summary
Summary
Medical AI should not be treated as a simple tool rollout. Based on WHO guidance and FDA documents, this article explains how companies can set up governance, monitoring, and change control before quality breaks down.
TL;DR
Key points first
- Define high-risk use cases and human review before deployment
- Treat prompt changes, source changes, and UI changes as managed updates
- Design monitoring and rollback conditions as part of normal operations
What you will learn
- Why medical AI governance must be designed before scaling
- How WHO and FDA thinking can be translated into company operations
- What should be documented for safe updates and supervision
Conclusion
If a company wants to use medical AI responsibly, it must define governance before scale. Human oversight, source management, change control, and post-launch monitoring should be treated as operating requirements, not optional refinements.
Background
WHO's 2025 guidance on large multi-modal models for health positions medical AI as a governance issue, not only a technology issue. It emphasizes human oversight, transparency, and post-deployment monitoring, especially in higher-risk contexts. [1]
The FDA's final guidance on predetermined change control plans also reinforces that changes expected after launch should be defined in advance, including what may change and how validation will be handled. For internal medical AI operations, this thinking applies directly to prompt changes, RAG source updates, and UI revisions. [2][3]
Practical actions
- Classify use cases by risk and define which ones require physician review
- Record source rules, prohibited outputs, and escalation conditions before rollout
- Treat model, prompt, source, and interface updates as managed changes with re-evaluation rules
- Prepare monitoring metrics and rollback conditions as part of normal operations
Sources
FAQ
Can we start with a lightweight PoC first?
Yes, but even a small PoC should define where human review happens, what sources are used, and what kinds of outputs are not allowed. Governance can be lighter at the beginning, but it still needs to exist.
Do we need physician review for every output?
Not always. The practical approach is to classify outputs by risk and define where physician review is mandatory, where operational review is enough, and where publication should be blocked.